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Abstract
Background: The prevalence and incidence of HCV infection varies geographically due to exposure to different risk factors. 
Identification of HCV genotype is important to defining the epidemiology of the disease. The objective of this study was to 
describe genotype distribution and its relation to risk factors among HCV infected patients attending virology clinic of the 
Department of Infectious Diseases at the Tripoli Medical Centre. Methods: The medical records of 891 Libyan chronic HCV 
infected patients registered and followed up from January 2003 to January 2007 were reviewed. Data gathered includes 
patient's age, gender, risk factors and family history of HCV infection. Statistical analysis was performed using t, x2 and 
contingency coefficient tests. Results: The mean age was 40.22±13.09 years. Two thirds of patients were males. Normal 
alanine aminotransferase (ALT) at diagnosis was found in 62% of the patients. HCV RNA < 2 million copies at diagnosis was 
found among 54% of patients. HCV genotype 1 (G1) was the most frequent (30.9%), followed by G4 (29.2%). Genotype 2 
affected 19.3% and G3 13.6%. No classification of HCV genotype was available for 2% of the patients. Many subtypes of HCV 
were detected with different frequencies (G1a and b, G2a, b, c and a/c, G3a and G4a and c/d). All genotypes of HCV were 
more common among males (P<0.001). Genotype 3 was the most frequent among male patients (88.6%). Regarding the risk 
factors, 33% of patients had a history of hospitalization and/or surgical procedures, and 22.7% had a history of blood 
transfusion. A past history of intravenous drug abuse (IVDA) was reported by 15% of the patients, and 15.9% reported a 
history of dental procedures. The relationship between the genotype of HCV and risk factors was statistically significant 
(P<0.001). No history of risky exposure was found among 10.8% of patients. Conclusion: Genotypes 1 and 4 were more 
predominant among HCV infected patients. Males were affected more than females and they presented themselves to the 
clinic at a younger age. The results of this study strongly suggest the need for implementing strict infection control measures 
in hospitals and dental clinics to reduce the nosocomial transmission of HCV, as well as measures to control the problem of 
intravenous drug users in the community. 
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Introduction
Hepatitis C Virus is the most frequent cause of chronic 
viral hepatitis in the world [1]. The prevalence and 
incidence of HCV infection varies geographically due to the 
evolution of risk factors [2]. Up to 80% of patients with 
acute viral hepatitis C develop chronic viral hepatitis [2]. 
In Libya, HCV infection has become a public health 
problem. A national sero-epidemiological survey showed 
that the prevalence of HCV antibodies in the general 
population was 1.2% [3]. 
 
HCV has marked genetic heterogeneity with nucleotide 
variability between different isolates [4,5]. Phylogenetic 
analysis indicates that there are at least 6 different 
genotypes of HCV and more than 90 subtypes [5,6]. HCV 
genotypes 1, 2 and 3 are distributed worldwide, whereas 
genotypes 4, 5 and 6 are found mainly in certain areas 
[6,7]. For example, genotype 4 is highly prevalent in Egypt 
and many central African countries [7-11]. Data on the 
genotype of HCV infections in Libya are scarce. One recent 
study from Benghazi showed that G4 was the most 
prevalent HCV genotype in the eastern part of the country 
[12].  
 
Some studies showed that there is little difference in the 
severity of disease or in the outcome of patients infected 
with different genotypes [13]. However, the genotype of 
HCV does affect recommendations and counseling 
regarding interferon treatment [14-16]. Moreover, when 
using combination therapy, the recommended dose and 
duration of treatment depend on the genotype of the virus 
[17,18]. Some studies showed that patients with 
genotypes 2 and 3 are more likely to respond to 
interferon-based therapy [17,18]. On the other hand, 
genotyping of HCV infection is helpful in defining the 
epidemiology of the disease because it does not change 
during the course of infection [1,2]. 
 
Genotype distribution of HCV has not been described 
before in Tripoli. The objective of this study was to 
analyze the genotype distribution and its relation to risk 
factors among chronic HCV infected patients attending the 
virology clinic of the Department of Infectious Diseases at 
the Tripoli Medical Centre. 
 
Methods
This study was carried out at the Tripoli Medical Centre. 
The medical records of 1279 Libyan chronic HCV infected 
patients were reviewed. These patients had been 
registered and followed up at the virology clinic of the 
Department of Infectious Diseases, Tripoli Medical Centre, 
from January 2003 to January 2007. Genotyping was done 
only for 891 of these patients (69.7%). 
 
Patient's age, gender and, in the initial screening, 
nationality were recorded. Non-Libyan patients were 
excluded from the study. Patients who had a history of 
hemodialysis were also excluded from the study. Data 
gathered included risk factors for HCV infection (history of 
blood transfusion with or without blood disease, 
intravenous drug abuse "IVDA", hospital admission with or 
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without surgical intervention, dental intervention, unsafe 
sexual activity and/or promiscuity). Ethical approval from 
the Department of Infectious Diseases at the Tripoli 
Medical Centre was obtained. 
 
Genotyping results of HCV were considered if they were 
performed by gene amplification by using the Cobas-
Amplicor HCV test (Roche Diagnostics, Basel, Switzerland) 
[19]. 
Data were analyzed using SPSS version 11.5 to identify 
the demographic characteristics and risk factors associated 
with the different HCV genotypes.  
The distribution of HCV genotypes, age, gender and risk 
factors of different groups were compared by using t, x2 
and contingency coefficient tests. 
 
Results
The patients’ ages ranged from 16 to 76 years with a 
mean of 40.22±13.09 years. The mean age of the males 
was 38.89±12.70 years and of the females 42.88±13.45 
years. The difference was statistically significant 
(P<0.001). 
 
Alanine aminotransferase (ALT) at diagnosis was normal 
in 62% of patients. HCV RNA < 2 million copies at 
diagnosis (low viral load) was found among 54% of 
patients. A positive family history of HCV infection was 
found among 3.2% of patients. 
 
Table 1 The demographic and clinical characteristics of Libyan 
HCV infected patients attending the virology clinic at the Tripoli 
Medical Centre 
Mean age and SD in years  40.22±13.09 
Mean age and SD in years by 
gender 
Males  38.89±12.70 
Females 42.88±13.45 
(P=0.000) 
Age range in years  (16-76) 
Normal ALT at diagnosis  62% 
HCV RNA < 2 million copies 
at diagnosis 
54% 
Family history of HCV 
infection 
3.2% 
 
Table 2 shows that genotype 1 was the most frequent 
genotype, occurring in 30.9% of the patients. Genotype 2 
was found in 172 patients (19.3% of patients), while 
genotype 3 infected 166 (13.6% of patients), and 
genotype 4 was found in 260 (29.2% of patients). 
Genotypes 5 and 6 were not detected at all in those 
patients. No classification of HCV genotype was available 
for 2% of the patients. 
 
Table 2 The distribution of HCV genotypes 
Genotype of HCV 
No of 
patients
Percent
Unclassified HCV  18  2 
Genotype 1   275  30.9 
Genotype 2  172  19.3 
Genotype 3   166  18.6 
Genotype 4  260  29.2 
The four genotypes and several subtypes were observed 
with different frequencies (Table 3). One quarter of the 
patients had unclassified genotype 4. Subtypes G2b and 
G4c/d were uncommon. Some patients were infected by 
more than one subtype, e.g. 3% of patients had G2a/c 
and 0.9% had G4c/d.  
 
Table (4) shows that two thirds of the patients were 
males. All HCV genotypes were more common among 
males and the difference from females was statistically 
significant (P<0.001). Genotype 3 was the most frequent 
among males (88.6%), followed by G1 (66.5%). 
Genotypes 2 and 3 were found among 59.9% and 56.9% 
of male patients, respectively. On the other hand, the 
most frequent HCV genotype among females was G4 
(43.1%) and the least common was G3 (11.4%).  
 
One third of the patients had a history of hospitalization 
and/or surgical procedures (Table 5). A history of blood 
transfusion was recorded among 22.7% of the patients. A 
history of dental procedures and IVDA was recorded 
amongst 15.9% and 15% of the patients, respectively. A 
minority of the patients (2.6%) had a history of sex with 
an HCV infected person and/or promiscuity. No history of 
any risky exposures was found among 10.8% of the 
patients. There was a significant relationship between the 
HCV genotype and risk factors for infection (P<0.001). 
 
Table 3 The distribution of subtypes of different HCV genotypes. 
Genotype/ subtype 
No of 
patients
Percent
Unclassified HCV  18  2 
G1a 72  8.1 
G1b 107  12 
G1 unclassified  96  10.8 
G2a 22  2.5 
G2b 7  0.8 
G2c 18  2 
G2a/c 27  3 
G2 unclassified  98  11 
G3a 19  2.1 
G3 unclassified  147  16.4 
G4a 25  2.8 
G4c/d 8  0.9 
G4 unclassified  227  25.5 
Total 891  100 
Genotypes 1 and 4 were detected more frequently 
among patients who had a history of blood transfusion, 
hospitalization, surgical procedures, sexual contact with an 
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HCV infected person, or promiscuity. Genotype 2 was 
found in one third of those who had a history of dental 
procedures. Genotype 3 was detected among 60.4% of 
patients who had a history of IVDA. Genotypes G1 and G4 
were predominant in patients who had a history of sex 
with an HCV infected person and/or promiscuity. 
Moreover, 35.7% of patients who had a history of 
hospitalization and/or surgical procedures were affected 
by G1 and 30.3% of them were affected by G4. Genotype 
4 was detected in 39.6% of those who had no history of 
risky exposure. 
 
Table 4 The distribution of HCV genotypes according to gender. 
For differences between males and females, X
2 = 50.367 and 
P<0.001. 
Genotype of HCV 
Males 
(%) 
Females 
(%) 
Total 
Unclassified HCV  12 (66.7)  6 (33.3)  18 
Genotype 1   183 (66.5)  92 (33.5)  275 
Genotype 2  103 (59.9)  69 (40.1)  172 
Genotype 3  147 (88.6)  19 (11.4)  166 
Genotype 4  148 (56.9)  112 (43.1)  260 
Total  593 (66.6)  298 (33.4)  891 
Table 5 The distribution of HCV genotypes according to risk 
factors. For the relationship between the HCV genotype and risk 
factors for infection, the contingency coefficient = 0.465, P<0.001 
Risk factor 
 
Un-
classifi
ed  
n 
 (%) 
G1  
n 
(%) 
G2  
n 
(%) 
G3 
n 
(%) 
G4 
n 
(%) 
Tota
l 
n 
(%) 
Blood 
transfusion 
14  
6.9 
65 
32.2 
39  
19.3 
18  
8.9 
66 
32.7 
202 
22.7 
Dental 
procedures 
0  
0 
36 
25.4 
47  
33.1 
17  
11.9 
42 
29.6 
142 
15.9 
IVDA 
0  
0 
35 
26.2 
0  
0 
81  
60.4 
18 
13.4 
134 
15 
Sexual 
contact with 
HCV infected 
person and/or 
promiscuity 
0  
0 
7  
30.4 
3  
13.1 
6  
26.1 
7 
30.4 
23 
2.6 
Hospitalizatio
n and/or 
surgical 
procedures 
3 
1 
105 
35.7 
63 
21.4 
34 
1.6 
89 
30.3 
294 
33 
Unknown 
1 
1.1 
27 
28.1 
20 
20.8 
10 
10.4 
38 
39.6 
96 
10.8 
Total  18 275  172  166  260  891 
Discussion
This study shows that HCV genotypes 1 and 4 are the 
more frequent genotypes among Libyan patients attending 
the virology clinic of the Department of Infectious 
Diseases at the Tripoli Medical Centre. A previous study 
conducted in Libya had shown that HCV infection with 
genotype 1 was more prevalent in the western region. A 
study in Tunisia (which borders the west of Libya) showed 
that genotype 1b was the most prevalent type of HCV 
infection (79%) [20]. The former study [12] also showed 
that genotype 4 was the most prevalent genotype in the 
eastern region of the country (63.6%), which resembles 
results reported from Saudi Arabia, where G4 were the 
most prevalent HCV among Saudi patients (62%), as well 
as among Egyptian patients living in Saudi Arabia [21].  
Our study shows that Libyan male patients presented at 
the medical centre at a younger age than females. 
Moreover, nearly two thirds of the patients were males, 
and all HCV genotypes were more frequent among males, 
especially G3. G3 could be more common among males 
because 60% of subjects with a history of IVDA had type 
G3, and most likely IVDA in Libya is much more common 
among males. 
 
Four genotypes and several subtypes were recognized 
with different frequencies, but genotypes 5 and 6 were 
not detected at all. Infection by more than one subtype 
occurred in a minority of cases. Importantly, we observed 
that the laboratory failed to classify the HCV genotype and 
subtype in many patients. 
 
We observed a statistically significant relationship 
between the HCV genotype and the risk factor for 
infection. A history of hospitalization and/or surgical 
procedures was reported by one third of the patients. 
Previous hospitalization is a known risk factor for HCV 
infection in some countries [22,23]. Nosocomial 
transmission is likely if disinfection procedures are 
inadequate and contaminated equipment is shared 
between patients [24,25]. Other common histories 
associated with the infection reported by the patients in 
our study were blood transfusion, dental procedures and 
IVDA. Only a few patients (2.6%) gave a history of sexual 
contact with an infected HCV person and/or promiscuity.  
 
Notably, 22.7% of the patients reported a history of 
blood transfusion. Worldwide, blood transfusion 
constitutes the most commonly recognized transmission 
mechanism of HCV [26].  
 
A past history of IVDA was reported by 15% of the 
patients, but IVDA carries an extremely high risk of HCV 
infection. Data from the Centres for Disease Control (CDC, 
Atlanta, USA) showed that from 1986 to 1988, IVDA was 
responsible for 42% of cases of acute hepatitis C [27]. 
Some studies showed that anti-HCV antibodies are present 
among 70 to 90% of IVDA [26]. 
 
The results of this study showed that a history of 
hospitalization and/or surgical procedures were more 
frequent among patients who had G1. A study from 
France had shown that genotype 1 is associated more 
commonly with blood transfusion [28]. Genotype 2 was 
not recorded among patients who had a history of IVDA, 
while genotype 3 was the most frequent one among those 
patients. A study from southeast France showed some 
similar results, where it was found that G3 was associated 
with IVDA [29]. Genotypes 2 and 4 were also common in 
patients who had a history of hospitalization and/or 
surgical procedures and blood transfusion. A positive 
family history of HCV infection was found only among a 
minority of patients.  HCV RNA < 2 million copies at 
diagnosis (low viral load) was found in approximately half 
of the patients. Nearly two thirds of the patients presented 
to the clinic initially with normal ALT.  
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Conclusion
Genotypes 1 and 4 are predominant among patients 
chronically infected with HCV and attending the virology 
clinic at the Tripoli Medical Centre. Twice as many males 
as females were infected with HCV and they presented 
themselves to the clinic at an earlier age. The most 
common risk factors were a past history of hospitalization 
and/or surgical procedures, blood transfusion, dental 
procedures, and intravenous drug abuse (IVDA). The 
results of this study constitute a strong indicator that strict 
infection control measures should be implemented in 
hospitals and dental clinics to reduce the nosocomial 
transmission of HCV, and that ways to reduce the number 
of intravenous drug users in the community should be 
sought. 
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